Prognostic Factors Associated with Resectable Adenocarcinoma of the Head of the Pancreas

Millikan, Keith W.; Deziel, Daniel J.; Silverstein, Jonathan C.; Kanjo, Tadge M.; Christein, John D.; Doolas, Alexander; Prinz, Richard A.
July 1999
American Surgeon;Jul1999, Vol. 65 Issue 7, p618
Academic Journal
Deals with a study that determined the prognostic factors that may influence long-term survival in patients with pancreatic cancer who have undergone pancreatic resection. Materials and methods; Results; Discussion.


Related Articles

  • Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections. Gangl, Odo; Sahora, Klaus; Kornprat, Peter; Margreiter, Christian; Primavesi, Florian; Bareck, Evelyne; Schindl, Martin; Längle, Friedrich; Öfner, Dietmar; Mischinger, Hans-Jörg; Pratschke, Johann; Gnant, Michael; Függer, Reinhold // World Journal of Surgery;Feb2014, Vol. 38 Issue 2, p456 

    Background: Despite significant improvements in perioperative mortality as well as response rates to multimodality treatment, results after surgical resection of pancreatic adenocarcinoma with respect to long-term outcomes remain disappointing. Patient recruitment for prospective international...

  • Standard Retrograde Pancreatosplenectomy versus Radical Antegrade Modular Pancreatosplenectomy for Body and Tail Pancreatic Adenocarcinoma. LATORRE, MARCO; ZIPARO, VINCENZO; NIGRI, GIUSEPPE; BALDUCCI, GENOVEFFA; RAMACCIATO, GIOVANNI; CAVALLINI, MARCO // American Surgeon;Nov2013, Vol. 79 Issue 11, p1154 

    Pancreatic surgery remains the only established curative treatment for pancreatic cancer. Radical antegrade pancreatosplenectomy (RAMPS) is a modification of the standard retrograde pancreatosplenectomy (SRPS) developed to achieve a complete N1 node resection and R0 resection (posterior extent)....

  • Definition of Microscopic Tumor Clearance (R0) in Pancreatic Cancer Resections. Schlitter, Anna Melissa; Esposito, Irene // Cancers;2010, Vol. 2 Issue 4, p2001 

    To date, curative resection is the only chance for cure for patients suffering from pancreatic ductal adenoacarcinoma (PDAC). Despite low reported rates of microscopic tumor infiltration (R1) in most studies, tumor recurrence is a common finding in patients with PDAC and contributes to extremely...

  • To deny or not to deny surgical resection for pancreatic cancer to elderly patients? Degrate, Luca; Bagnariol, Francesca; Nobili, Cinzia; Ogolong, Patricia; Poli, Silvia; Franciosi, Claudio; Romano, Fabrizio; Caprotti, Roberto; Uggeri, Franco // BMC Geriatrics;2009 Supplement 1, Vol. 9, Special section p1 

    Background Population over 65 years old represents the fastest growing group of overall population. Considering that almost 70% of pancreatic cancer patients are over 65 years old, therefore an increasing number of elderly patients should be considered for pancreatic resective surgery. The aim...

  • Pancreatic cancer - surgical options. Ihse, Ingemar // Gastroenterologia Polska / Gastroenterology;2009, Vol. 16 Issue 2, p103 

    Pancreatic cancer surgery has progressed significantly during recent years and it is still the only treatment alternative with a chance for cure. In this review the pros and cons of the different surgical options are scrutinized. As extended pancreaticoduodenectomy does not improve survival the...

  • Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma. Sugiura, Teiichi; Uesaka, Katsuhiko; Kanemoto, Hideyuki; Mizuno, Takashi; Sasaki, Keiko; Furukawa, Hiroyoshi; Matsunaga, Kazuya; Maeda, Atsuyuki // Journal of Gastrointestinal Surgery;May2012, Vol. 16 Issue 5, p977 

    Objective: To evaluate the preoperative factors predictive of postoperative early recurrence in patients with resected pancreatic cancer focusing on the serum CA19-9 value. Methods: One hundred fifty-four patients undergoing surgical resection for pancreatic cancer were enrolled in this study....

  • ULOGA HIRURÅ KE RESEKCIJE U TRETMANU ADENOKARCINOMA PANKREASA. MILOŠEVIĆ, Pavle; ĐOLAJI, Matilda; MILOŠEVIĆ, Đorđe; IKONIĆ, Nada; POPOVIĆ, Ana; VELJKOVIĆ, Radovan // Medicinski Pregled / Medical Review;Sep/Oct2011, Vol. 64 Issue 9/10, p448 

    Introduction Pancreatic adenocarcinoma is the fifth leading cause of death from malignant diseases. The total five-year rate is bellow 5%, but in patients who underwent pancreatic resection, the five-year rate may be up to 20%. Surgical resection is still the only therapeutic option that offers...

  • Pancreatic Resections for Advanced M1-Pancreatic Carcinoma: The Value of Synchronous Metastasectomy. Seelig, S. K.; Burkert, B.; Chromik, A. M.; Tannapfel, A.; Uhl, W.; Seelig, M. H. // HPB Surgery;2010, Vol. 2010, p1 

    Background. For M1 pancreatic adenocarcinomas pancreatic resection is usually not indicated. However, in highly selected patients synchronous metastasectomy may be appropriate together with pancreatic resection when operative morbidity is low. Materials and Methods. From January 1, 2004 to...

  • Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. Endo, Hisahito; Saito, Takuro; Kenjo, Akira; Hoshino, Mika; Terashima, Masanori; Sato, Tetsu; Anazawa, Takayuki; Kimura, Takashi; Tsuchiya, Takao; Irisawa, Atsushi; Ohira, Hiromasa; Hikichi, Takuto; Takagi, Tadayuki; Gotoh, Mitsukazu // Journal of Hepato -- Biliary -- Pancreatic Sciences;Jul2012, Vol. 19 Issue 4, p465 

    Purpose: To determine the feasibility, safety and histological change of preoperative endoscopic ultrasound-guided fine-needle injection (PEU-FNI) of immature DCs (iDCs) with OK-432 in pancreatic cancer patients. Methods: Nine patients enrolled in the trial (DC group) and were compared with 15...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics